Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024
Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024
早前報道，Lyell發佈了IMPt-314的1-2期結果，強調了在2024年ASH大會上b細胞淋巴瘤治療的療效和可控的安全性。
- Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior lines of therapy
- Manageable safety profile with no high-grade cytokine release syndrome (CRS) and low rates of Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS); adverse events were resolved with standard treatment protocols
- Initial clinical data are consistent with clinical experience from UCLA trial of CART19/20, a product candidate with the same CAR construct as IMPT-314 that has demonstrated durable responses in a Phase 1 trial of patients with non-Hodgkin lymphoma
- 在接受IMPt-314治療的CAR t-初治大B細胞淋巴瘤患者中，客觀反應率（ORR）爲94%，完全反應（CR）率爲71%。
- 安全性可控，沒有高等級細胞因子釋放綜合症（CRS），3級免疫效應細胞相關神經毒性綜合症（ICANS）的發生率較低；不良事件通過標準治療方案得到了解決。
- 初步臨床數據與來自UCLA的CART19/20試驗的臨床經驗一致，該產品候選者的CAR構造與IMPt-314相同，並在針對非霍奇金淋巴瘤患者的1期臨床試驗中展示了持久反應。